UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 243

Sortiert nach

Artificial Intelligence and Machine Learning: Will Clinical Pharmacologists Be Needed in the Next Decade? The John Henry Question

Clinical pharmacology and therapeutics, 2020-04, Vol.107 (4), p.697-699

Corrigan, Brian W.

2020

Volltextzugriff (PDF)

Role of Disease Progression Models in Drug Development

Pharmaceutical research, 2022-08, Vol.39 (8), p.1803-1815

2022

Volltextzugriff (PDF)

Clinical Pharmacokinetics of Pregabalin in Healthy Volunteers

Journal of clinical pharmacology, 2010-08, Vol.50 (8), p.941-950

2010

Volltextzugriff (PDF)

Disease progression meta-analysis model in Alzheimer's disease

Alzheimer's & dementia, 2010-01, Vol.6 (1), p.39-53

2010

Volltextzugriff (PDF)

Comparing five equations to estimate glomerular filtration rate or creatinine clearance and assign individuals to KDIGO categories across the full age spectrum using real world data

Clinical and translational science, 2024-02, Vol.17 (2), p.n/a

2024

Volltextzugriff (PDF)

Fishery catch records support machine learning-based prediction of illegal fishing off US West Coast

PeerJ (San Francisco, CA), 2023-10, Vol.11, p.e16215-e16215, Article e16215

2023

Volltextzugriff (PDF)

Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures

Epilepsia (Copenhagen), 2011-02, Vol.52 (2), p.248-257

2011

Volltextzugriff (PDF)

Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID‐19

Clinical pharmacology and therapeutics, 2020-08, Vol.108 (2), p.201-211

2020

Volltextzugriff (PDF)

Quantitative Prediction of Renal Transporter-Mediated Clinical Drug–Drug Interactions

Molecular pharmaceutics, 2013-11, Vol.10 (11), p.4207-4215

2013

Volltextzugriff (PDF)

Further Developments in the Use of Semipermeable Membrane Devices as Passive Air Samplers: Application to PCBs

Environmental science & technology, 2001-11, Vol.35 (22), p.4536-4543

2001

Volltextzugriff (PDF)

Further Developments in the Use of Semipermeable Membrane Devices (SPMDs) as Passive Air Samplers for Persistent Organic Pollutants: Field Application in a Spatial Survey of PCDD/Fs and PAHs

Environmental science & technology, 2001-06, Vol.35 (12), p.2576-2582

2001

Volltextzugriff (PDF)

How modeling and simulation have enhanced decision making in new drug development

Journal of pharmacokinetics and pharmacodynamics, 2005-04, Vol.32 (2), p.185-197

2005

Volltextzugriff (PDF)

Pharmacometrics as a Discipline Is Entering the "Industrialization" Phase: Standards, Automation, Knowledge Sharing, and Training Are Critical for Future Success

Journal of clinical pharmacology, 2010-09, Vol.50 (S9), p.9S-19S

2010

Volltextzugriff (PDF)

Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID‐19, in Subjects With Renal Impairment

Clinical pharmacology and therapeutics, 2022-10, Vol.112 (4), p.892-900

2022

Volltextzugriff (PDF)

F5‐03‐04: Application/qualification of disease models for improved treatment development in Alzheimer's Disease

Alzheimer's & dementia, 2011-07, Vol.7 (4S_Part_23), p.S810-S811

Corrigan, Brian

2011

Volltextzugriff (PDF)

Application/qualification of disease models for improved treatment development in Alzheimer's Disease

Alzheimer's & dementia, 2011-07, Vol.7 (4), p.S810-S811

Corrigan, Brian

2011

Volltextzugriff (PDF)

Patient Centric Microsampling to Support Paxlovid Clinical Development: Bridging and Implementation

Clinical pharmacology and therapeutics, 2024-01, Vol.115 (1), p.42-51

2024

Volltextzugriff (PDF)

Improved Utilization of ADAS-Cog Assessment Data Through Item Response Theory Based Pharmacometric Modeling

Pharmaceutical research, 2014-08, Vol.31 (8), p.2152-2165

2014

Volltextzugriff (PDF)

Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data

Clinical pharmacology and therapeutics, 2020-04, Vol.107 (4), p.796-805

2020

Volltextzugriff (PDF)

Ensuring diversity in clinical trials: The role of clinical pharmacology

Contemporary clinical trials, 2022-07, Vol.118, p.106807-106807, Article 106807

2022

Volltextzugriff (PDF)

Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database

Journal of Alzheimer's disease, 2013-01, Vol.37 (1), p.173

2013

Volltextzugriff (PDF)

Demographic diversity of participants in Pfizer sponsored clinical trials in the United States

Contemporary clinical trials, 2021-07, Vol.106, p.106421-106421, Article 106421

2021

Volltextzugriff (PDF)

Serials Spoken Here

Serials review, 2022, Vol.48 (1-2), p.181-187

2022

Volltextzugriff (PDF)

Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database

Alzheimer's & dementia, 2011-03, Vol.7 (2), p.151-160

2011

Volltextzugriff (PDF)

Training the next generation of pharmacometric modelers: a multisector perspective

Journal of pharmacokinetics and pharmacodynamics, 2024-02, Vol.51 (1), p.5-31

2024

Volltextzugriff (PDF)

1 – 25 von 243

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(207)
Mit Volltextzugriff
(211)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Artificial Intelligence and Machine Learning: Will Clinical Pharmacologists Be Needed in the Next Decade? The John Henry Question

Role of Disease Progression Models in Drug Development

Clinical Pharmacokinetics of Pregabalin in Healthy Volunteers

Disease progression meta-analysis model in Alzheimer's disease

Comparing five equations to estimate glomerular filtration rate or creatinine clearance and assign individuals to KDIGO categories across the full age spectrum using real world data

Fishery catch records support machine learning-based prediction of illegal fishing off US West Coast

Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures

Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID‐19

Quantitative Prediction of Renal Transporter-Mediated Clinical Drug–Drug Interactions

Further Developments in the Use of Semipermeable Membrane Devices as Passive Air Samplers: Application to PCBs

Further Developments in the Use of Semipermeable Membrane Devices (SPMDs) as Passive Air Samplers for Persistent Organic Pollutants: Field Application in a Spatial Survey of PCDD/Fs and PAHs

How modeling and simulation have enhanced decision making in new drug development

Pharmacometrics as a Discipline Is Entering the "Industrialization" Phase: Standards, Automation, Knowledge Sharing, and Training Are Critical for Future Success

Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID‐19, in Subjects With Renal Impairment

F5‐03‐04: Application/qualification of disease models for improved treatment development in Alzheimer's Disease

Application/qualification of disease models for improved treatment development in Alzheimer's Disease

Patient Centric Microsampling to Support Paxlovid Clinical Development: Bridging and Implementation

Improved Utilization of ADAS-Cog Assessment Data Through Item Response Theory Based Pharmacometric Modeling

Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data

Ensuring diversity in clinical trials: The role of clinical pharmacology

Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database

Demographic diversity of participants in Pfizer sponsored clinical trials in the United States

Serials Spoken Here

Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database

Training the next generation of pharmacometric modelers: a multisector perspective

Suchergebnisse filtern